Drug-coated 0.035" angioplasty balloon

Find similar products

Stellarex drug-coated balloon (DCB), featuring EnduraCoat technology, provides top-tier patency to treat common-to-complex lesions with a low drug dose. Low clinically driven target lesion revascularization rates demonstrate the safety of Stellarex across all patients.

  • 1. Mathews S. NCVH, 2018. ILLUMENATE Pivotal Stellarex DCB IDE Study 2-Year Outcomes. May 30, 2018. New Orleans, LA.
  • 2. Brodmann M. ILLUMENATE EU RCT: 2-year Results; Oral Presentation. VIVA 2017, Las Vegas, NV. September 11-14, 2017.
  • 3. Laird, et al. J Am Coll Cardio. 2015;66:2329-2338. In.Pact Summary of Safety and Effectiveness Data (SSED). Medtronic In.Pact Instructions for Use, M052624T001 Rev 1F.
  • 4. Holden. Comparing Trials Data in the Management of Calcified Arteries. Charing Cross 2018. April 24-26, 2018; London, UK.
  • 5. Zeller. ILLUMENATE Global: 12-month results with the Stellarex DCB in femoropopliteal lesions. LINC. 2017. Leipzig, Germany.
  • 6. Bard Lutonix Instructions for Use, BAW1387400r3.
  • 7. Zeller. ILLUMENATE Global: 2-year results with the Stellarex DCB in femoropopliteal lesions. LINC. 2018. Leipzig, Germany.
  • 8. Stellarex IFU. P011966-D.
  • 9. Lyden S. Oral presentation, TCT 2016, Washington DC. Nov 2, 2016.
  • 10. Data on file. D044595-00.
  • 11. Schroeder H. et al. Circulation 2017;135:2227-2236
  • 12. H. Schroeder et al. Catheter Cardiovasc Interv. 2015.
  • *VasCore (Boston, MA); PSVR: 2.5, KM estimates at day 365 (360 for IN.PACT SFA) Studies shown are not head-to-head comparisons, and data presented cannot be directly compared. Calcium definitions may vary from study to study, and the rates presented here are based on those used and reported in each respective study. Complex patients refers to high rates of severe calcium, diabetes and renal insufficiency estimates. Primary patency based on Kaplan-Meier.